
    
      The study has 3 cohorts. Cohort 2 and cohort 2-SC will be conducted in parallel with some
      data presented combined.

      Cohort 1 - Participants will receive 100 mg Tabalumab (LY2127399) intravenously (IV), 1.3
      milligram per square meter (mg/m^2) bortezomib IV, and 20 mg dexamethasone orally.

      Cohort 2 - Participants will receive 300 mg Tabalumab (LY2127399) IV, 1.3 mg/m^2 bortezomib
      IV, and 20 mg dexamethasone orally.

      Cohort 2-SC - Participants will receive 300 mg Tabalumab (LY2127399) IV, 1.3 mg/m^2
      bortezomib subcutaneously (SC), and 20 mg dexamethasone orally.

      Cohort 2-SC was added per protocol amendment in February 2013.
    
  